TTNP - Earnings call transcript Q3 2018 | Titan Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for holding. And welcome to the Titan Pharmaceuticals Third Quarter 2018 Financial Results Conference Call. At this time all participants are in a listen-only mode. There will be a question-and-answer session following today's remarks. Please be advised that this call is being taped at the company’s request, and will be archived on the company’s website starting later today. would President turn Pharmaceuticals. and I to call time, Bhonsle, Sunil CEO this like the to over At of Titan go ahead. Please

Sunil Bhonsle

Welcome we to results we for Thank And for third I But quarter call thank before and XX, with filed the press update inform wanted that our XX-Q this today. you review to on and can XXXX, issued on summary the report also September us. our be business. and to SEC operational a you, Pharmaceuticals an found of the begin, and the you titanpharm.com. results financial quarterly release Form ended provides on Titan to afternoon, at provide Sean, website joining all our the

Vice today recently But Officer; are provide Crowley, our Titan of of the update financial President on Executive Joining regarding results statements. President review Dr. Beebe required our forward-looking call before our me Chairman; the into cautions company, and details and Executive Commercial on the Chief Executive the our Hallberg, appointed we Rubin, and Dane an Kiernan and go DeVarney, Jennifer? Vice Kate Dr. Vice Chief will the Brian Officer; Marc President Jennifer Scientific Finance. from

Jennifer Kiernan

actual uncertainties undertaking development Securities drug of Thank results, management’s and and will and approval obligation relating any other risks within current intellectual affect Such development, statements marketing that statements Probuphine; required matters; that risks any the revisions you, programs limited that and herein expectations, to or be our of Such everyone and negatively historical of Securities now relationships. in by cause to, any any XXXX. Sunil. uncertainties that results circumstances any that events, And to stock are and may the include, patent business, change statements contained expectations relating include statements the I facts. reflect materially XXA Exchange to XXXX statements forward-looking of and expressly of our our you, publicly not the our contain operating forward-looking the any meaning the want regulatory candidates; those certain agreements could statements Factors conditions to discussed commercialization but product or involve of to than price. We in law. and financial updates disclaim based, changes matters such are is Act not any to could Section historical any and remind Act Sunil. process; Section differ information today XXE from other strategic property on to production or as except testing, release or back to conditions statement which of

Sunil Bhonsle

from will start Jennifer. will summarize the regulatory development and then results. I with your for Brian will affairs financial on an a the Chairman; who our Rubin introduce overview our questions. brief rents with Today Officer, medical provide Kate Dr. activities Crowley progress opening you, our we Probuphine close other the Probuphine an recap also and And our call will Thank Dr. plans. Hallberg. product DeVarney, And Chief Dane activities. discuss commercialization before programs, call then on Commercial will the will Executive update Dane

get let's So Marc? started.

Marc Rubin

all you. Thank of Sunil. hello, welcome you much, to very and And

program number third to notable expand also of opportunities our The related and technology with was to our of XXXX a its Probuphine ProNeura lead achievements quarter to there application. platform marked by

of few begin me let by highlights. the a mentioning So

a pleased Opioid of State using or September, or to to or September, $X.X with in X-year, in grant, Probuphine very later pilot million Abuse early justice Nevada on national Drug who were were NIDA. we for Health, treat awarded Institute Then the system. Use designed the Behavioral Center we from we treatment Nevada criminal within MAT evaluate announce a to First, the are that is OUD initiated that Disorder program programs patients medication-assisted

because Those of We sold with of Titan's the with also option strengthened notable the focus exercises together XXXX. a our priority. $XX through of and overallotment balance our the my about sheet today, quarter by activities top us supporting on the will in the accomplishments, are minutes. and want commercialization which each closing colleagues Probuphine my in offering, offering, public on provided to an warrants comments net runway But few extends subsequent the our underwritten in this all U.S., proceeds is elaborate million, of third which I

other and launches leading marketing intelligence across multiple Implanon successful highly its Bristol-Myers marketing and Dane experience depth research products. brings project been access. business cultivating thought goal decades transition and strong initiative Tierra two to I'm And Sunovion our guidance over retained a to market member commercial who, healthcare launching relationships and an was is the both leader health Officer. by that the building knowledge and biotech commercial in implant development, oversight have the market leading global third impressive by to economics has He very Executive building research commercial started important recently key the infrastructure. and Squibb Chief contraceptive and capabilities, Japan, strong to outcomes product Dane also the to end by and global roles responsible Most Able in teams. Our our in say, President And a and with Hallberg, for analytics establishment Incorporated, complete and strategic sales, and sales we including very that end, in has teams provide Dane recently XXXX. enterprise commercial programs. also and this foundation of was team industries. the specialties, pleased of where Star, Dane and pharmaceutical to Healthcare and among includes record management stage of a of Titan subdermal Global for Japan, leadership Dendrite track was This and Vice and access marketing is the was Merck, of sales the experience, of Commercial Pharmaceuticals, for position appointed he quarter,

say saying, it So extremely at for with any have to executive without Dane? Dane will our And important commercialization. will to joined but that Dane activities over we the this Titan's role company. key fortunate very I that, goes this turn discuss supporting are time team Probuphine's to in way call I the

Dane Hallberg

role. Thank you I'm new very excited Titan this much, join to Marc. in

the In was on with Probuphine, largely addition commercialization to any. interruption, epidemic. Probuphine am some third has Titan's potential optimistic ability Titan's the in being The that and minimal the supply focus opioid key re-launch Probuphine's we chain and use of quarter the to I'm while to activities access. in successfully activities term, patients to disorder Probuphine needs to transitioning report providers the healthcare the included I significant continuing global during logistics providers. unmet opportunities if functions that address and to identified engage the quarter, healthcare provide in third to prescribing confident happy during market supply better long and for transfer of service maintaining

be team, We've in we the commercial logistics, rapid next and in third-party mentioned, compliance, Marc experienced to and coming accomplished is As sales weeks. marketing, medical expertise have highly and yet a payer regulatory made a completed their training sales, small, expected engaged access. progress team chain supply building with

for We supply regulations engage also only substance. functions, purpose as access and chain but consultants and with seasoned appropriate, we've market of team a commercializing have not a such navigating proven where controlled of us the managing assisting the

third during been We professionals the very able of and are continuity transition to patients, healthcare have REMs certified of their revenue maintain this meaningful delivery quarter, pleased to during Probuphine to period. generating

Probuphine where patients can for We allowing penetration market growth. and provide are targeting sales meaningful sustained segments market for selected benefit

We prescribing are focusing physicians oriented with long-term treatment on high programs. Probuphine recovery

specialty partners engaging to ensure with the and right proactively are broad access. pharmacy payers We contracting third-party patient

market reimbursement of for in supply and label are to data, access top paving expansion. can assess clinically the our longer-term, the could possibility addition, investigator potentially future some engage the research of facilitate which that way tier the in help process. Probuphine In some meaningful may the We that provide specialists improve providers chain sponsored us the believe

help at system the to of justice residential program segments. in in Health, criminal reflects academic facility and a many large deal and treatments groundwork generate Behavioral of initiated in number use There epidemic. our the system, the OUD pilot setting Nevada justice growing for laying system The continue recently the within treatment strategy will market which we facilities enable opioid of part are incarceration program, of with supports justice We addiction of the addiction parole residential this rise pilot Center data like is management the term. efforts. of rates program treatment criminal part use increasing was A drug Treatment Probuphine program expected U.S. the has could prevention treatment part and to this MAT that The recidivism. the the do criminal Probuphine in of become The not of product disorder, reducing of of as use high of incarceration Assisted of the a or substantially the opioid near course with Medication is Part hopes to post-discharge been MAT, program relapse. use with of goal regimen. the

establish to disorder with a few opioid Probuphine plan programs MAT use we use that of and integrate alliances such, As treatment. part as large can

of as Probuphine affairs, Scientific and safety Probuphine increased Probuphine, with on that DeVarney, and institutions the use including also as we to turn as Kate plan That equipment that focus call In opinion Chief in functions, building small compliance and said, summary, regulatory well safety complement their of compliance on Officer, team our team. who growth future are work to near-term program. and development an with will we our their healthcare we our trained act procedures drug utilization I supporting appropriate. on leveraging for the key being for providers for Dr. will likely progress could activities. In to a advocacy current medical alliances the strong hand-in-hand Titan's currently personnel our providers are conducting drug we with number who identifying developing already these plan initiatives product efforts, prescribing and Probuphine form product endeavor, Kate? Finally, as discuss have be support patients and our of a to and leaders, support benefit. are foundation advocates this over who educational a of working will

Kate Beebe DeVarney

And Dane. excited I’m to you you, Thank our on so team. have

Probuphine. product to lead overview of Let me with start related activities recent our an

experienced have community to expertise Probuphine with August, early few affairs the new medical as has activity been administered as strategy numerous on essential allows the we program providers, and for skills also third departments, facilitates whom have our are it medical or well the liaison medical sessions and part Probuphine evaluation risk quarter, with the and healthcare experience engage they conducted Since The and their of Probuphine of an a of well highly building their healthcare We professionals, certified training. established compliance. the relationships, hired We’ve the as drug REMS safety directly through Probuphine as training latter. treatment their providers. activities team program training as knowledge with During each science providers. gain previously that medication program. REMS REMS and two firsthand strong needs transition, medical new, as This

EMA we that to of in Now ex-U.S. support MAA year. we continue Probuphine review to late partner terms our the activities, last submitted Molteni the as

on is first all the During questions. from interactions process, by third MAA. several respond with closely half with of and for the with worked in remain initial This our we their standard the review agency XXXX. Molteni EMA to their agency of the We to the the a during questions decision address of to rounds track raised quarter, a

Therapeutics Now in with month. launch disorder the at use end its of of of Probuphine, announced last patients of the this April approval for commercial stable treatment maintenance following Health the Knight opioid Canada's year, the

Although Therapeutics, Probuphine previously Knight in agreement double-digit stage, a for in we received a license this for implantation on Titan's by to commercial study IV of has, Canada. lower an physicians conducting as reimplantation as evaluate far, a very site Probuphine patient's Under alternate sales. safety this abdomen. been of low the requirement very entitled is In we in post-marketing also so first The the well percentage by royalty well the understand quarter, early FDA. Probuphine Canadian aim used preparations with Phase of arm pharmacokinetics inner initiated location upper in into on into Probuphine

hope FDA patients. asses with design design. safety and the the feedback their valuable to targeted believe to trial We that Both study FDA year. in XXXX, design cohort providers healthcare its also studies of for we required on received the Phase in another the observational IV implant are by of an study data procedure from finalize for And and just initiation will end we provide

to a Center U.S., mentioned, using Nevada initiated medication program Dane Behavior supports a as the the and use patients the its with programs criminal opioid treatment the for assisted to Finally, here pilots within with with evaluate system criminal Probuphine generating meaningful State with justice selected also of disorder. that program of Health, potentially for goal other the establish We Nevada use pilot population. justice plan in important of Probuphine we data similar

Phase the tolerability trial enrollment second patients to quarter announced to implant that pharmacokinetic to in of cohort our we program. from Monitoring the DSMB proceed completed We review third Parkinson's safety, disease next Data Board from the Moving the early Independent of and implant. had ropinirole the the of that The the first cohort our recommended Safety profile. X/X continue its study data with

development, of we elected positive enrollment postpone second to of patients. the cohort Although a

strategy additional ProNeura-based indication, can some our platform resources of products today our made decision news successful exciting on potential to thing many And the pipeline. our a coming of is focus long-term expansion to opportunities to the in last as While and the I technology our the on month. highlight as pursue will its re-launch we've to is apply of we Probuphine

of the X-year again As NIDA year through NIDA, previously the NIDA awarding from XXXX, in Marc XXXX have these awarded the NIDA very Titan Probuphine, provides to million studies grant of grant will portion grant, of the now for in of the Nalmefene, grant availability a mentioned, August control during availability are of we potential support antagonist, to second funding and of funding IND-enabling grateful to who approximately relapse for addiction September. trial years the a remainder opioid of we The grant providing formulation successfully six-month of our successful to will If funding. funds XX $X.X has $X.X by approximately on its continued opioid approximately ProNeura-based and million X million and of in were implantable patients grant another subject detoxification program. for prevention NIDA. progress an us. are is considered Phase that to on successful development a in of undergone fund supported the clinical application IND-enabling of $X.X be and depending the X a This

keeping we've see, look several really busy and next as progress productive quarter. you over third I on updated had So months. the you a can And forward to

I'd like turn Brian to the Titan's results. Now to call to discuss financial Brian?

Brian Crowley

million in Thank you, with Form all I'll Kate. details press key and numbers, rounded, therefore, note quarter been this a provide, time, items. Please this in property the A $X.X of that XXXX, Molteni and in about approximate. of deferred summary from to the European $X.X the filed the In highlight available sale of reflect SEC the $X.X Molteni, Probuphine are and for I'm the same At financial results revenue of release rights third have period agreement XXXX March few revenue XX-Q are License was purchase the to related just in $XX,XXX related the today. compared a we've in our to provided reported afternoon million of the revenues intellectual issued year the August the to approximately XXXX. amendment million ago. XXXX to period of the amortization

the reacquiring generating Probuphine from our we revenue $XXX,XXX sales. addition, commercialization had quarter product since first of In rights,

expenses, $X.X the from same consisting in to quarter, XXXX. of quarter third primarily G&A million expenses, operating and For compared $X.X million total were the R&D

quarter XXXX. underwritten of provided through of $X.X in as a third Our quarter, closed in of XXXX million, option we of per the of quarter equivalents net $X.X with the combined third of received of We compared the planned that At XXXX, of and sale September the was from the $X.XX a of our which $X.X same or $X.XX $X.X common third sufficient offering, million, overallotment this is the loss shares to million. and we shareholders believe warrants In recent the result operations per previously cash exercise net public loss of outstanding share, of or the fund announced attributable $X.X quarter cash net the share, to with remaining end had underwriters million exercises XXXX. the proceeds million.

pass will the Sunil. to call back I Now,

be I the have at during Q&A you the happy If end to any the questions, them will presentation. Sunil? address of

Sunil Bhonsle

everyone. you Thank

our we As you a have heard advance U.S. have hard Probuphine to to successful and commercialization under in accomplish from the sales this team, goal. proven we working are leadership, re-launch marketing dedicated Dane's strategies to of the And been

of the affairs, and safety a and facilities. additional addiction that together to these the has prescribing process. them work make patients already engaging criminal improving compliance team, primary commercial healthcare we foundation activities. is reimbursement capable residential a a to the position for she team. treatment available strong As key programs have Officer to companies. payer strategic And are on built for taken This expect from Kate focus And and put benefit providers a in successful is academic training with providers now very Chief healthcare we a address through system, the identify that our with strong medical I market partnerships win-win it Scientific other justice complementary the all. Probuphine, Probuphine, to and mentioned, have additional for market to entry to certified I our in likely potential we complements their With role segments, medical and with responsibilities right believe commercial in to for queries. segments is while ongoing long-term third-party be easier started already in the growth

strategy, studies ProNeura And important patients our other pursue allow. our potential resources remain fully on has We've of today. continue to initiating will product executed and programs an the platform concludes with part growth as X remarks required that be products, shall ProNeura-based year. advance we once the the recognized chronic development next disease, prepared benefit have while to clinical This our the Probuphine these company's development other we of the will We re-launch. we Probuphine for Phase

the would continued for Sean, questions of to ready from board executive hard take Before the to staff I and work like management thank their I we’re open call participants. dedication. to questions, call and Titan's

Operator

from Ben. Our question Ben Please go Alliance Global comes first Instructions] Haynor [Operator Partners. with ahead

Ben Haynor

off, starting what of there had was a from So there prescribers? you you've months. just in guess, on, are prescribe I to curious just implantations? color their QX would Any increasing guys several have existing be so quite or obviously, you eventful I from like seen yes, last continued provide or kind pretty Are could far helpful. they prescriptions -- they

Sunil Bhonsle

a from providing have a will the flavor the the we Ben. great for third Dane sales quarter, Sure, how progressing. are product you things reported And question. and occurring. obviously for we that But continued are It’s I give let sales

Dane Hallberg

market is Titan happy Probuphine to we Thank this. for found that they're Probuphine Yes, is to the Sunil. never we've extremely to We’ve that the what so market. support with discussing Sure. out going traditionally prior the have from science-based continued access you, and physicians into company. the commercialized a

that, for able a to the provide we've REMS a those training on leads to expiratory training, clinicians. trainers quickly able their locations been our foundation science Kate's those team, been recertify -- to to up to In initial concert with are facilitates we've REMS access strong working So teams or that medical get Probuphine. say coming were physician on to really with set

peer as been us very engaged the had. that their the of as also some with, discussions we've Probuphine excited the They're response very access members. well we've has from positive market to overall, supporting physicians the about So

been it's very all-in-all, positive. So

Ben Haynor

having or is that level? the up the don't me from about, down month monthly just a in on your themselves Is there that you or physicians a come in X data drop-off about they've each And on don’t looks patients if payers that's out about subsequent could of I XX% with competitor with out to get markets the it and depot patient XX% for, months now your either so, it that injection thinking the shared that or conversations to injection.

Dane Hallberg

-- is that has the therapy. way actually I So paved what is happened believe long-term what that actually the MAT

treatment. and really that what are there injections. I like It's a think monthly monthly patients injection. And providers about we're months six the the Probuphine not is So a

to Probuphine a rods. going not they You're the see when drop-off insert

have the that our think favorability those is terms positive the I fairly towards of treatment. for products in So dropped-off

Ben Haynor

mean, I What going Yes, yes, that's know. are the now? expected But, to validate. you never

Dane Hallberg

Right.

Ben Haynor

criminal Nevada corrections the the systems with department about know, the justice have can are process think thinking yet and you had or waiting Nevada. done from -- program? have first anything from with there? just justice agreement or you they later? that are people that you would willing implants the Or you to provide criminal then, Have rather And and I there if discussions I than opportunity, that great. And any other so, jurisdictions have sooner color you

Kate Beebe DeVarney

criminal That's very a great program closely in question, Yes, is this is Nevada. pilot Ben. Center we the Health, with been in leading have system Kate. working for Hi, this which justice Behavioral

We have got response approximately healthcare providers. a that chain. of healthcare to XX the very, We positive providers throughout for very their XX trained

the clinically the would a are stable for a dose stage That's gaining of of go. provider coming And All of to are be that And appropriate patients which healthcare are. They patients entire are a or be at initiative who aware, expect is according as this process we to less are recertified weeks the criminal the system. very orders justice that we there months treatment. -- complicated where system probably on the labeling, day X in and you identifying -- patients that they coming it's product across in system. to them are ready appropriate milligrams and

Ben Haynor

It's That got - the question. you've next my of population. was incarcerated obviously kind

the got You've probation population.

or once that not particular? been you've of another have in from to Hasn’t You the gotten the those thinking buy-in navigate of populations populations couple difficult of. I'm managers? it relatively has gone smoothly visitors probably Or any it

Kate Beebe DeVarney

two done now. we've for Nevada actually right -- group training trainings first our At the

the had there you is the the different The clinically etcetera. of uniform system is a the any from product, this appropriate jails, as treatment because stage had imagine, the system, first process. half all represents anybody passage justice And acceptance court and incarceration we can this criminal a for way drug is in that of is training representatives interest the

that coming coming to I hopeful and of But in some we’re see now going patients the said, treatment. weeks the orders for we’re So process months. the as in identifying right we’re

Sunil Bhonsle

And Ben, this Sunil. is

Just keep incarcerated mind to to add one not that treatment before. of has place something been in patients thing that has in been

like manage when to to that. have major a and like a things they So this of so how endeavor, the internal will making state on commitment Nevada is they and and takes that handle to it will and they procedures are their follow-ups they all how the it, on patients establish own

than that what it exactly fits, of get seeing are they establish system. we need more here. thinking long-term patient a And let’s where on So and really just to Probuphine them simple, it, are will so a as the helping what that's happen that benefits establish

So I expect sort to that states follow. model a of see this in creating can other building

program. important it's So an

Ben Haynor

too much into are a that, And of the a place then, in that digging stable patients in in implanted follow-up eventually, on all all the on being that. that If potentially daily to in are that treatments jail that? lead prison, for patients they occurs and the would that am I I Nevada? guess, if Or that’s get or protocol

Kate DeVarney Beebe

identification we but are the it disorder, of that patients. and across had untreated. all largely the opioid in Well, what Board, think And and XX% stages U.S it, the appropriate that know to the would is people, criminal lead Nevada, justice of not across the it's in in system use in who of I just

of So this lot a is people.

pilot small what a That’s highest overdose. right and is potential desperately objective them, way here have the we rate released with program, very so that a sure especially we’re high they treat they relapse need the once understand our these really are for. And we to and of aiming treatment. then patients that starting protect We’re make who to

Ben Haynor

I And it's ones quick from right. all then, me guess more two if

a like but those On taking might that minimum could the to the trials, future sounds you the label sponsored Or the actually guys sponsored you just extend do do trails any investigator help the that FDA? add investigator the it from not in new trials will label? data expand to the inform

Kate DeVarney Beebe

or to is supplemental And initiated good very are That not Don’t question. sponsored drug and applications. trials investigator lead typically new investigator sufficient.

it with certainly regulatory I in seen is past. different that picking required in-house worked programs What that [ph]. in to companies for development both meet the they're for valuable to would I've up we SNBA ways lead done of However, ideas all signals that conduct then the larger very an though very, submission for requirements would the

Ben Haynor

the been just that or are me? you And helpful. can the ballpark very a then exercises outstanding kind warrant exercised XX% for in and quite like things. that look That’s that scheme lastly, it of saw looks warrants have you few of Does that like of kind

Sunil Bhonsle

million It's the about $XX or $XX XX%. roughly of million It's so.

Operator

Our from John. Zacks Vandermosten John next comes SCR. with ahead Please question go

John Vandermosten

just cash on the flow a had question I couple issues.

that I what come going should And supposed Nalmefene, or supposed to we -- that to to and flows? period over come Is think, The first was rightly on $X.X in. expect to that million over come see is those when is that's pronounced.

Sunil Bhonsle

The grant of first August September $X.X from year, for period, itself of up end the of really is million, over is year. million period that is a X-year year this and and $X.X next to the to the

will the million, XXXX. year, $X.X which year is September the That So end with the of million bit of $X.X year of timeframes. up literally it's terms during first next in and -- that's But period. odd little in for second August starting that sort to XXXX

-- is development work and doing upon IND I necessary. cash initial the and the year based non-clinical work second all is that the is of is flow So mostly the geared formulation the part year towards towards work, then mean for supporting first

that's it's So how split-up.

John Vandermosten

the And over the fiscal the or year those come it at notably at of thing? graphs end Okay. whole beginning to of that period or

Sunil Bhonsle

we over of are the time available costs. period funds as See, incurred the

period. will submit We then reimbursement that during them for

the at the of end based actually expenditures. not actual it’s upon is year. throughout So It the year

John Vandermosten

what on side quarterly cash related second might of the question we can give the allocated just if see we modeling And Second that on that. burn about might when just But getting be great. would cash any the Phase X. And the half help I'm rate you effort? impression flow to kind see 'XX

Sunil Bhonsle

Sure. are there key John, Kate two setting studies, as this described. in

is a a the lot in a in -- number one be where to important used very a sense a re-implanting or study smaller is second but that the patients the and The are one. compared looking first as previously we at smaller think costing it's of previously million. study, this site of study And will indicated full well, be study, million study. will as will it That timeframe start next site. it's year. part will years to X $X $X early the end-up in years And something that to we X.X roughly new had for I It

John Vandermosten

Okay.

Sunil Bhonsle

Okay.

second start to know is it. right a but study. have we the details. prospective sort want that study, study give you'll And When the a mention now. larger study, But of observational actually much observational don't The I a to I once, the mean, study. is numbers I it's

the of the We discussed being the worked FDA. all details things that with haven't yet still are out

don't type million I timeframe. sometime $X in And of this start latter So have yet be over And sometime to of will the much. next should of mean exact part I start place. to only to going it in going more comparison. And and is the really protocol it's sense I expensive. expensive, thing be X-year probably the in that a But year. is say will the not million it's but $X how

John Vandermosten

-- and because different same the helpful. mean, Will U.S. right getting I'm that of United that the there face some that hurdles out things plans again, I November. obvious, any I'm they started? can moving for very that may any And assume about are they about, That of is you face anticipated? Braeburn faced they excited States. head just on the But health the have are up point worried to in in in And there that Canada, that wondering, are sales now, there Okay. I hurdles the

Sunil Bhonsle

very there of -- medications, obviously, and get Therapeutics own detail. I general, they there. pricing this. their announcements the want and wait and The something up different of of Knight But has is including different a into than populations public It's had that quite that different, with of availability in to different and pros, on, don't terms injectables different here. till on. structure is set the so in use In the marketing so are the on the to lot healthcare I strategy mean make that

cannot in who for urban easily on, thing really haven't at the this come-up be where suited. do or So patient is doctor they all saying, looked approach, implants believe hey, of would population a looked ideally they populations very regions with an at or in targeted I I best and clinic are say a have not really and would instance, what be And a good get with Canada targeting. implant strategy cannot can they quickly and to a approach and suited that's

John Vandermosten

that. Braeburn some think those I when just that like was or structured. two wondering I thinking just was systems, that's was one REMS mean, things the And of way of of don’t that the the question, I of it's that but and don’t hurdles with, Canadian reimbursement I easier any it's because asking that experienced but then hurdles just exist fair, and felt know the I

Sunil Bhonsle

their does they Once from better to there. is with all But Canada will I’m over put get clearly, to lot drug. I'm different easier the approval essentially way bit treatment. pricing own within they healthcare regions it. the driver new the for easier is Little access primary the it their of with not payer system, the have hurdles as sure, -- everyone third-party

John Vandermosten

think, Dane. payers, question a very and for was pursue that to getting Dane. And is for question on I patients I wondering congratulations was that approach last was maybe And strategy was progressing to ask think, team, out the three-pronged there of on, I a is And it. going distant update about, how that's how And three-pronged … just that I and physicians. working?

Dane Hallberg

the good promotional with to their with FDA before to to --bringing that approach place. approved strong put the means in having review submitting regulatory in physicians government all of with group been internally OPEB those and put to Absolutely, understand the And we are their engagements foundation has that our that question. are patients' place, ensure caregivers. absolutely. to fundamentals Yes, working their the needs, compliance The materials strong a really ensure with to needs,

how caregivers to to segmentation understand in we with our more really whys. and to delivering making to patients, that, the providers along do we We were the have So you're the effective can to and the why payers, properly, be overall, to the members. understand a company and as clinicians, Probuphine asking why to or healthcare therapy

patient feedback, to their payers want amount so correct you always access. get MAT right that right we with first assimilate to physicians you that, that discussions, with generally, have or long-term with of those have as well when hurdles well, Whenever access. that you a down So their were still and and that to finding populations. reduce treat Along we drug, patients as to we to assemble therapy, the the for launch the are they the we have launch the messaging, obstacles

Probuphine. to within So are in the understand as pharmacy has to get segments. to utilized and quickly feedback they well patient major thoughts long-term talk as on something the populations we that of players are MAT directors medical overwhelmingly response And directors that the see want from very been country therapies their and the certain positive some their to

orders. uptake seen really in so have a strong And we

into -- And the stronger see so first even uptake next year. I going quarter believe we an can we'll of

were as for have long us. we a areas, as in able so, path see the folks And the right clear to I right

Operator

to remarks. the Sunil conclude I like question-and-answer now any would for will to call session. turn our Bhonsle Mr. closing This over

Sunil Bhonsle

forward us and support to really you continue again I year. your early a day. talking all all the certainly great everyone. guys meantime, is in from do next you happy to to everybody, call. to you Thank conference our appreciate participating keep Sean. will you, time. your this Thank It we goal ongoing and updated And over to have I of In so. Thanksgiving look

Operator

Thank The now and for you attending conference disconnect. has you today's presentation now may concluded.

Titan Pharmaceuticals (TTNP) 14 Nov 182018 Q3 Earnings call transcript